Showing 101–125 of 136 · North America
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Recent change of ownership; current owner not yet confirmed from official filings.
Financial health not assessed until ownership and accounts are verified.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
FY2026 revenue $5.65bn (+9.9%); operating margin 33.4%; net income $1.52bn.
Cash $1.47bn; debt $659.4m.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
FY2026 revenue $41.52bn (+10.0%); operating margin 20.1%; net income $7.46bn.
Cash $7.33bn; debt $14.44bn.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
FY2025 revenue $8.32bn (+0.9%); operating margin 26.2%; net income $1.56bn.
Cash $878.0m; debt $5.04bn.
FY2025 revenue $139.7m (+1.5%); operating margin 14.1%; net income $15.9m.
No debt; $25.3m cash.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
FY2025 revenue $25.12bn (+11.2%); operating margin 19.5%; net income $3.25bn.
Balance sheet figures not captured from release.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
FY2025 revenue $2.53bn (-1.5%); operating margin -10.4%; net loss $200.3m.
Cash $781.1m; debt $994.9m.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Part of TELUS (T.TO).
Latest full-year results not yet captured by HSH.
FY2025 revenue $1.27bn (+83.4%); operating margin -19.9%; net loss $245.0m.
Cash $759.7m; debt $1.24bn.
FY2025 revenue $44.56bn (+3.9%); operating margin 17.4%; net income $6.70bn.
Cash $9.85bn; debt $39.38bn.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
FY2025 revenue $346.8m (+1.4%); operating margin 6.0%; net income $4.4m.
Cash $24.9m; debt $164.6m.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Parent Siemens Healthineers (SHL.DE) group FY2026 revenue €23.60bn; adjusted EBIT margin 16.2%.
Comparable revenue growth 4.0%; adjusted EBIT about €3.8bn. Net income not captured.